[1]
|
J. Das Neves, “Vaginal drug delivery”. 2008, SciTopics.
|
[2]
|
J. Robinson, W. Bologna, “Vaginal and reproductive system treatments using a bioadhesive polymer”. J Control Rel. Vol. 28, 1994, pp. 87-94.
|
[3]
|
A. Gursoy, A. Bayhan, 2007) “Testing of drug release from bioadhesive vaginal tablets. Drug Dev Ind Pharm. Vol. 17, No. 18, 2007, pp. 2457-2475.
|
[4]
|
European Pharmacopoeia 60: EDQM (2007).
|
[5]
|
British Pharmacopoeia. London: Stationary Office; 2009.
|
[6]
|
United States Pharmacopoeia and National Formulary, 2009.
|
[7]
|
A. El-Kamel, M. Sokar, V. Naggar, “Bioadhesive controlled release metronidazole vaginal tablets”, Acta Pharm, Vol. 52, 2002, pp. 171-179.
|
[8]
|
S. Garg, L. Jambu, K. Vermani, “Development of novel sustained release bioadhesive vaginal tablets of Povidone Iodine. Drug Dev Ind Pharm. Vol. 33, 2007, pp. 1340- 1349.
|
[9]
|
F. Ahmad, M. Alam, Z. Khan, M. Khar, M. Ali, “Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed infections”. Acta Pharm, Vol. 58, 2008, pp. 407-19.
|
[10]
|
L. Wang, X. Tang, “A novel Ketoconazole bioadhesive tablet for vaginal delivery: Design, in vitro and in vivo evaluation”. Int J Pharm. Vol 350, No. (1-2). 2008, 181-187.
|
[11]
|
C. Lee, Y. Chien, “Development and evaluation of mucoadhesive drug delivery system for dualcontrolled delivery of nonoxynol-9”. J Control Rel., Vol. 39, 1996, pp. 93-103.
|
[12]
|
C. Valenta, C. Kast, I. Harich, “Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone”. J Control Rel. Vol. 77, No. 3, 2001, pp. 323-332.
|
[13]
|
V. Kale, R. Trivedi, P. Muley, (2008) “Proposed Design of a Dissolution Apparatus for Vaginal Formulations Containing Probiotics”. Dissolution Technologies. Vol. 15, No. 2, 2008.
|
[14]
|
P. Rege, V. Vilivalam, C. Collins, “Development in release testing of topical dosage forms: use of Enhancer cell with automated sampling”. J Pharm Biom Anal, Vol. 17, 1998, pp. 1225-1233.
|
[15]
|
W. Liebenberg, E. Engelbrecht, A. Wessels, “(2004) A comparative study of the release of active ingredients from semisolid cosmeceuticals measured with Franz, Enhancer or Flow through cell diffusion apparatus. J Food Drug Anal. Vol. 12, No. 1, 2004, pp. 19-28.
|
[16]
|
J. Nuttall, D. Thake, M. Lewis, (2008) “Concentrations of Dapivirine in the Rhesus Macaque and Rabbit following Once Daily Intravaginal Administration of a Gel Formulation of [14C] Dapivirine for 7 Days. Antimicrob Ag Chemother, Vol. 52, No. 3, 2008, pp. 909-914.
|
[17]
|
K. Vermani, S. Garg S, (2000) The scope and potential of vaginal drug delivery. Pharm Sci Tech Today. Vol. 3, No. 10, 2000, pp. 359-364.
|
[18]
|
D. Owen, D. Katz, “A vaginal fluid stimulant”. Contraceptives, Vol. 59, 1999, pp.91-95.
|
[19]
|
A. Woolfson, R. Malcom, R. Morrow, “Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide”. Int J Pharm. Vol 325, No.1-2, 2006, 82-89.
|
[20]
|
K. Gupta, S. Pearce, A. Poursaid, 2008) “Polyurethane Intravaginal Ring for controlled delivery of Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor of HIV-1”. J Pharm Sci. Vol. 97, No. 10, 2008, pp. 4228-4239.
|